Previous Close | 101.80 |
Open | 102.10 |
Bid | 104.55 x 0 |
Ask | 104.95 x 0 |
Day's Range | 102.10 - 104.45 |
52 Week Range | 85.26 - 105.90 |
Volume | |
Avg. Volume | 0 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Nov 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
The latest trading day saw Cardinal Health (CAH) settling at $111.76, representing a -0.2% change from its previous close.
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.